GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Public ClinicalTrials.gov record NCT01316939. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 52 Week Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease
Study identification
- NCT ID
- NCT01316939
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- GlaxoSmithKline
- Industry
- Enrollment
- 229 participants
Conditions and interventions
Conditions
Interventions
- GSK1605786A Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 8, 2011
- Primary completion
- Oct 22, 2013
- Completion
- Oct 22, 2013
- Last update posted
- Sep 6, 2017
2011 – 2013
United States locations
- U.S. sites
- 54
- U.S. states
- 27
- U.S. cities
- 51
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Little Rock | Arizona | 72205 | — |
| GSK Investigational Site | Tucson | Arizona | 85712 | — |
| GSK Investigational Site | La Jolla | California | 92093 | — |
| GSK Investigational Site | San Diego | California | 92103 | — |
| GSK Investigational Site | San Francisco | California | 94115 | — |
| GSK Investigational Site | Aurora | Colorado | 80045 | — |
| GSK Investigational Site | Lakewood | Colorado | 80215 | — |
| GSK Investigational Site | Littleton | Colorado | 80120 | — |
| GSK Investigational Site | Hamden | Connecticut | 06518 | — |
| GSK Investigational Site | New Haven | Connecticut | 06510 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| GSK Investigational Site | Jacksonville | Florida | 32256-6004 | — |
| GSK Investigational Site | Port Orange | Florida | 32127 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342-5006 | — |
| GSK Investigational Site | Suwanee | Georgia | 30024 | — |
| GSK Investigational Site | Chicago | Illinois | 60637 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46237 | — |
| GSK Investigational Site | Lexington | Kentucky | 40536-0298 | — |
| GSK Investigational Site | Hammond | Louisiana | 70403 | — |
| GSK Investigational Site | Monroe | Louisiana | 71201 | — |
| GSK Investigational Site | Chevy Chase | Maryland | 20815 | — |
| GSK Investigational Site | Towson | Maryland | 21204 | — |
| GSK Investigational Site | Towson | Maryland | 21286 | — |
| GSK Investigational Site | Boston | Massachusetts | 02114 | — |
| GSK Investigational Site | Ann Arbor | Michigan | 48109-5682 | — |
| GSK Investigational Site | Chesterfield | Michigan | 48047 | — |
| GSK Investigational Site | Troy | Michigan | 48098 | — |
| GSK Investigational Site | Rochester | Minnesota | 55905 | — |
| GSK Investigational Site | Lee's Summit | Missouri | 64064 | — |
| GSK Investigational Site | Mexico | Missouri | 65265-3726 | — |
| GSK Investigational Site | Brooklyn | New York | 11206 | — |
| GSK Investigational Site | East Setauket | New York | 11733-9292 | — |
| GSK Investigational Site | Great Neck | New York | 11021 | — |
| GSK Investigational Site | Lake Success | New York | 11042 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599-7080 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28207 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28209 | — |
| GSK Investigational Site | Durham | North Carolina | 27710 | — |
| GSK Investigational Site | Raleigh | North Carolina | 27612 | — |
| GSK Investigational Site | Columbus | Ohio | 43215 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74135 | — |
| GSK Investigational Site | Portland | Oregon | 97225 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| GSK Investigational Site | Germantown | Tennessee | 38138 | — |
| GSK Investigational Site | Nashville | Tennessee | 37212-1610 | — |
| GSK Investigational Site | Ogden | Utah | 84405 | — |
| GSK Investigational Site | Christiansburg | Virginia | 24073 | — |
| GSK Investigational Site | Danville | Virginia | 24541 | — |
| GSK Investigational Site | Norfolk | Virginia | 23502 | — |
| GSK Investigational Site | Richmond | Virginia | 23249 | — |
| GSK Investigational Site | Seattle | Washington | 98101 | — |
| GSK Investigational Site | Seattle | Washington | 98195 | — |
| GSK Investigational Site | Madison | Wisconsin | 53792 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 202 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01316939, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2017 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01316939 live on ClinicalTrials.gov.